Obesity is increasingly recognised as a chronic, relapsing medical condition rather than a lifestyle concern. This medicalisation of obesity represents a fundamental shift in global healthcare strategy and long-term healthcare investment priorities.
In December 2025, the World Health Organization formally acknowledged obesity as a condition requiring sustained medical treatment. This reframing positions obesity care alongside other chronic disease treatment systems such as diabetes and cardiovascular health, transforming it into essential healthcare infrastructure.
Globally, more than one billion people live with obesity, driving substantial economic and healthcare system pressure. Public healthcare systems remain structurally under-resourced, accelerating demand for scalable healthcare platforms capable of expanding access without replicating traditional cost-heavy models.
Breakthrough GLP-1 therapies have catalysed this shift, but the real investment opportunity lies in the delivery infrastructure that supports long-term care, patient compliance, and ongoing health outcomes.
As obesity treatment becomes embedded within national healthcare strategies, the sector increasingly reflects characteristics of long-duration infrastructure rather than discretionary healthcare spend.
Legal & Regulatory Notice
Important Notice
This article is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer to invest. The information is intended solely for High Net Worth Individuals and Sophisticated Investors as defined under applicable regulations. Past performance is not indicative of future results. Investments in healthcare and wellness sectors involve risk, including potential loss of capital. Independent financial, legal, and tax advice should be sought before making any investment decision.
